Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra (fo ...

Visualizations (Seaborn-styled): Scatterplot: Plots Subscription_Year vs. Subscription_Month to explore temporal relationships. Line Plot: Shows subscription counts by month to identify trends. Box ...